Investor Relations

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta® (lefamulin), approved by the FDA in 2019 for both Oral and IV use, and CONTEPO (fosfomycin) for injection. The approval of CONTEPO has been impacted by FDA’s travel restrictions due to COVID-19. We have engaged with the FDA to determine next steps for CONTEPO. In July 2020, Nabriva Therapeutics entered into an exclusive agreement with Merck & Co. Inc., to promote and distribute SIVEXTRO (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and adolescent patients for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and Fort Washington, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Thursday November 18, 2021 8:00 AM EST
Jefferies London Healthcare Conference

Monday September 13, 2021 7:00 AM EDT
H.C. Wainwright 23rd Annual Global Investment Conference

SEC Filings

Filing date Description Form Filing Group View

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS
Registration Statements
View HTML

UPLOAD

UPLOAD
Other
View HTML

Registration statement for certain foreign private issuers

F-1
Registration Statements
View HTML

Investor Contacts

E-mail: IR@nabriva.com

 

Data Provided by Refinitiv. Minimum 15 minutes delayed.